Date:	--/--/-- --:--:--
Event Id:	E5DAXA1HX
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	VIGL
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	8
Price Per Share Currency:	USD
News References:	https://www.globenewswire.com/news-release/2025/05/21/3086232/0/en/Press-Release-Sanofi-to-acquire-Vigil-Neuroscience-Inc-adding-a-new-investigational-medicine-to-treat-Alzheimer-s-disease-to-the-neurology-pipeline.html

Action Notes

Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi's four strategic disease areas, enhances Sanofi's early-stage pipeline and includes VG-3927, which will be evaluated in a phase 2 clinical study in Alzheimer's disease. VG-3927 is an oral small molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer's disease.